OncoResponse studies the immune systems of patients who are “elite responders” to cancer immunotherapies in order to develop new treatments for a broader array of cancer patients.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $153.1M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | GreatPoint... | gpv.com/ |
| - | Takeda Ven... | takeda.com |
| - | Reimagined... | reimagined... |
| - | 3B Future ... | 3bfuturehe... |
| - | Canaan Par... | canaan.com |
| - | Helsinn In... | helsinninv... |
Funding Rounds 7
| Date | Series | Amount | Investors |
| 18.05.2023 | - | $27M | - |
| 31.03.2021 | Series C | $40.6M | - |
| 11.09.2018 | Series B | $40M | - |
| 09.03.2017 | Series A | $22.5M | - |
| 10.10.2016 | Series A | $7M | - |
| 10.10.2016 | - | $3.5M | Helsinn In... |
| 29.05.2016 | Series A | $12.5M | - |
Mentions in press and media 23
| Date | Title | Description | Source |
| 18.05.2023 | OncoResponse lands $27M to advance development of antibody-b... | — Seattle biotech company OncoResponse landed $27 million to advance the development and testing of ... | geekwire.c... |
| 31.03.2021 | Seattle biotech OncoResponse raises $40.6M to create antibod... | Clifford Stocks. (OncoResponse Photo) New funding: OncoResponse raised a $40.6M Series C investment ... | geekwire.c... |
| 31.03.2021 | OncoResponse Raises $40.6 Million Series C Financing | – New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies | 3bfuturehe... |
| 31.03.2021 | OncoResponse Raises $40.6 Million Series C Financing | - New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies - Adds Magneta... | marketscre... |
| 18.06.2019 | Houston’s Startups Are Now an Entrepreneurial Powerhouse | Houston is the most ethnically diverse metropolitan area in the U.S and is expected to become the th... | startupgen... |
| 12.09.2018 | Term Sheet — Wednesday, September 12 | REBOOT REPRESENTATION Good morning, Term Sheet readers. Paid Content Securing the enterprise without... | fortune.co... |
| 11.09.2018 | OncoResponse raises $40M Series B to target immunotherapy ‘e... | The company’s approach consists of tapping “elite responders,” meaning patients who have responded w... | medcitynew... |
| 11.09.2018 | OncoResponse Raises $40M in Series B Financing | OncoResponse, a Seattle, WA-based immunotherapy company developing a portfolio of novel antibodies t... | finsmes.co... |
| 11.09.2018 | OncoResponse Grabs $40M | SEATTLE, WA, OncoResponse today announced the completion of a $40 million series B equity financin... | vcnewsdail... |
| 11.09.2018 | OncoResponse raises $40M to start clinical trials of antibod... | (Bigstock Photo) OncoResponse, a Seattle biotech company creating antibody-based treatments for canc... | geekwire.c... |
Show more